NASDAQ:GBT

Global Blood Therapeutics Stock Forecast, Price & News

Most-Downgraded Stocks

$49.92

+0.15 (+0.30 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$49.10

Now: $49.92▼

$50.68

50-Day Range

$40.57

MA: $44.62▼

$49.77

52-Week Range

$36.49

Now: $49.92▼

$87.54

Volume1.35 million shs

Average Volume860,916 shs

Market Capitalization$3.09 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.39

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

MarketRank^™

Overall MarketRank^™

1.60 out of 5 stars

Medical Sector

251st out of 1,558 stocks

Pharmaceutical Preparations Industry

130th out of 638 stocks

4.4 Analyst's Opinion

Consensus Rating
Global Blood Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $96.67, Global Blood Therapeutics has a forecasted upside of 93.6% from its current price of $49.92.
Amount of Analyst Coverage
Global Blood Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Global Blood Therapeutics has received 541 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Global Blood Therapeutics has received 353 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Global Blood Therapeutics has received 60.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote “Outperform” if you believe GBT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Global Blood Therapeutics does not currently pay a dividend.
Dividend Growth
Global Blood Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Global Blood Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Global Blood Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Global Blood Therapeutics are expected to grow in the coming year, from ($3.98) to ($3.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Global Blood Therapeutics is -10.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Global Blood Therapeutics is -10.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Global Blood Therapeutics has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GBT

Previous Symbol

CUSIPN/A

CIK1629137

Webwww.gbt.com

Phone650-741-7700

Employees352

Debt

Debt-to-Equity Ratio0.16

Current Ratio7.63

Quick Ratio7.20

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.11 million

Price / Sales1,462.11

Cash FlowN/A

Price / Cash FlowN/A

Book Value$9.61 per share

Price / Book5.19

Profitability

EPS (Most Recent Fiscal Year)($4.71)

Net Income$-266,770,000.00

Net Margins-332.94%

Return on Equity-56.43%

Return on Assets-39.32%

Miscellaneous

Outstanding Shares61,800,000

Market Cap$3.09 billion

Next Earnings Date2/24/2021 (Estimated)

OptionableOptionable

$49.92

+0.15 (+0.30 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

How has Global Blood Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GBT stock has decreased by 9.0% and is now trading at $49.92.
View which stocks have been most impacted by COVID-19.

Is Global Blood Therapeutics a buy right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Global Blood Therapeutics?

Wall Street analysts have given Global Blood Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Global Blood Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Global Blood Therapeutics.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.25. The business had revenue of $37 million for the quarter, compared to analysts' expectations of $44.56 million. Global Blood Therapeutics had a negative return on equity of 56.43% and a negative net margin of 332.94%. During the same quarter last year, the business posted ($1.07) EPS.
View Global Blood Therapeutics' earnings history.

What price target have analysts set for GBT?

18 analysts have issued 12 month price targets for Global Blood Therapeutics' stock. Their forecasts range from $45.00 to $152.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $96.67 in the next year. This suggests a possible upside of 93.6% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Global Blood Therapeutics' key competitors?

Some companies that are related to Global Blood Therapeutics include Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Ionis Pharmaceuticals (IONS), Arrowhead Pharmaceuticals (ARWR), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Allakos (ALLK) and Galapagos (GLPG).
View all of GBT's competitors.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:

Dr. Ted W. Love, Pres, CEO & Director (Age 62, Pay $1.14M)
Mr. Jeffrey S. Farrow, CFO & Principal Accounting Officer (Age 59, Pay $689.62k)
Dr. Brian Edwin Cathers, Chief Scientific Officer (Age 51, Pay $651.74k)
Mr. David L. Johnson, Chief Commercial Officer (Age 52, Pay $708.12k)
Dr. David R. Phillips, Founder & Advisor
Mr. Matthew P. Jacobson, Founder & Advisor
Dr. Andrej Sali, Founder & Advisor
Ms. Nazila Habibizad, Sr. VP of Operations
Stephanie Yao, Sr. Director of Corp. Communications & Investor Relations
Ms. Tricia Borga Suvari, Chief Legal Officer & Sec. (Age 60)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (0.23%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics.

Which institutional investors are buying Global Blood Therapeutics stock?

GBT stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
View insider buying and selling activity for Global Blood Therapeutics or or view top insider-buying stocks.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $49.92.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $3.09 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 352 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here